Skip to Content

Join the 'Tecentriq' group to help and get support from people like you.

Tecentriq News

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two cases where patients with advanced melanoma died of heart trouble two weeks after receiving their first doses of Opdivo (nivolumab) and Yervoy (ipilimumab). One patient was a 65-year-old woman who died following a rapid heartbeat and organ failure, while the other patient was a 63-year-old man who died after two rounds of sudden cardiac arrest. With a heart attack, blood flow to the heart is blocked and tissue damage occurs, while in the case of sudden cardiac arrest the heart suddenly stops ... Read more

Related support groups: Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Melanoma - Metastatic, Opdivo, Keytruda, Tecentriq, Yervoy, Nivolumab, Pembrolizumab, Campath, Lemtrada, Ipilimumab, Alemtuzumab, Atezolizumab

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Posted 19 Oct 2016 by Drugs.com

South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that Tecentriq helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.74, 95% CI: 0.63, 0.87). The study enrolled people ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Tecentriq, Atezolizumab

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of the American Association for Cancer Research (AACR). The AACR issued the news on immunotherapy as part of its 2016 Cancer Progress Report. As the group explained, more types of cancer are being successfully treated with immunotherapy. This treatment involves adding new cancer-fighting cells to the body or adding new elements, such as antibodies and proteins, to help the immune system fight cancer. In August 2015, one class of immunotherapy drugs – called checkpoint inhibitors – was approved for ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Melanoma, Bladder Cancer, Melanoma - Metastatic, Opdivo, Head and Neck Cancer, Hodgkin's Lymphoma, Keytruda, Tecentriq, Nivolumab, Pembrolizumab, Atezolizumab

Immune-Based Drug May Help Some With Advanced Bladder Cancer

Posted 5 Jun 2016 by Drugs.com

SUNDAY, June 5, 2016 – Patients with advanced bladder cancer can sometimes be too old or unhealthy to withstand standard chemotherapy. However, some may gain hope from a new drug that unleashes the immune system to attack tumor cells, researchers reported Sunday. Patients who responded to the drug Tecentriq (atezolizumab) had an average survival of nearly 15 months, about 5 to 6 months longer than people usually gain from platinum-based chemotherapy, said lead researcher Dr. Arjun Balar. The treatment didn't help everyone, however: Only about a quarter of patients responded to the drug. Still, any advance for this patient population is sorely needed, experts say. That's because about half of advanced bladder cancer patients cannot receive chemotherapy because they're too old to withstand chemo's toxic effects, explained Balar, who is assistant professor of medicine at NYU Langone ... Read more

Related support groups: Cancer, Bladder Cancer, Tecentriq, Atezolizumab

FDA Approves New Drug to Treat Bladder Cancer

Posted 31 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – A new drug to treat bladder cancer was approved by the U.S. Food and Drug Administration on Wednesday. Tecentriq (atezolizumab) treats the most common type of bladder cancer, called urothelial carcinoma. It's the first in its class of drugs, called PD-1/PD-L1 inhibitors, approved to treat this type of cancer. "Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway," Dr. Richard Pazdur, director of the office of hematology and oncology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body's immune system and its interaction with cancer cells," he added. The FDA approved Tecentriq for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has ... Read more

Related support groups: Bladder Cancer, Tecentriq, Atezolizumab

FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma

Posted 18 May 2016 by Drugs.com

May 18, 2016 – The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer. "Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. "Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body’s immune system and its interaction with cancer cells." Tecentriq targets the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells). By blocking these interactions, Tecentriq may help the body’s immune system fight cancer cells. Tecentriq is the first FD ... Read more

Related support groups: Cancer, Bladder Cancer, Tecentriq, Atezolizumab

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Urothelial Carcinoma, Bladder Cancer

Tecentriq Patient Information at Drugs.com